Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Advarra Inc

Neither a doctor nor a teaching hospital

Research payments

$1,695,542

1,382 payments

Through program year 2025, Advarra Inc is reported as receiving $1,695,542 in research payments, across 1,382 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $138,532 91
2024 Research $431,302 406
2023 Research $333,291 270
2022 Research $215,144 190
2021 Research $307,715 158
2020 Research $208,711 194
2019 Research $60,848 73

Breakdown

Who paid Research payments · program years 2019–2025
  1. Abbott Laboratories $664,631 593 payments
  2. Celgene Corporation $209,785 17 payments
  3. Novartis Pharmaceuticals Corporation $183,147 8 payments
  4. MacroGenics, Inc. $157,308 332 payments
  5. E.R. Squibb & Sons, L.L.C. $78,350 92 payments
  6. H. Lundbeck A S $65,285 16 payments
  7. Bavarian Nordic A/S $43,722 36 payments
  8. Amgen Inc. $38,085 7 payments
  9. Novocure Inc. $35,730 23 payments
  10. AveXis $30,805 21 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase III Randomized Study to Assess the Efficacy and Safety of Alpelisib (Byl719) in Combination With Olaparib in Patients With No Germline Brca Mutation Detected, Platinum-Resistant Or Refractory, High Grade Serous Ovarian Cancer $138,511 3 payments
  2. Phase II / III Pediatric CD study - A Phase 2/3, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Oral Ozanimod (RPC1063) in Pediatric Participants with Moderately to Severely Active Cr $127,920 2 payments
  3. Ph III Iberdomide vs. Revlimid post ASCT Maintenance NDMM TE $70,020 2 payments
  4. Lu Af28996 in Participants With Parkinson's Disease (PD) $65,285 16 payments
  5. A Phase 4, Global, Randomized, Double-blind, Placebo-controlled, Safety and immunogenicity Study of CHIKV VLP Vaccine in Children 2 to <12 Years of Age. $43,722 36 payments
  6. A Study of Two Dose Levels of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer $39,398 99 payments
  7. A Study of Lorigerlimab With Docetaxel Or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer $35,382 71 payments
  8. Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation $34,225 25 payments
  9. Portico NG Approval Study $29,810 19 payments
  10. Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation (SUMMIT) $29,040 30 payments
What the money was spent on Research payments · program years 2019–2025
  1. Other $167,710 338 payments
  2. Patient care $19,170 11 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record